Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer

Zhang,Cheng; Han,Yong; Huang,Hao; Min,Li; Qu,Like; Shou,Chengchao

doi:10.3892/ijo.2014.2352

Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer

Authors:
- Cheng Zhang
- Yong Han
- Hao Huang
- Li Min
- Like Qu
- Chengchao Shou
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: March 20, 2014 https://doi.org/10.3892/ijo.2014.2352
Pages: 2025-2033

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple-negative breast cancer (TNBC) shows more aggressive clinical behavior and poorer outcome than non-triple-negative breast cancer (NTNBC), and cannot be treated either via endocrine therapy or by Trastuzumab. For TNBC, chemotherapy is currently the mainstay of systemic medical treatment, the lack of more efficient options of treatment has been a problem in breast cancer prevention. In this study, we aimed to find genes related to prognosis in TNBC by bioinformatic analysis and to provide therapeutic candidates for TNBC treatment. We compared the differences in gene expression levels between cancer patients and healthy individuals across five breast cancer microarray databases to generate a gene cohort specifically upregulated in the NTNBC subtype, whose expression levels are ≥2-fold higher in TNBC compared to NTNBC and healthy individuals. Another two databases with clinical information were applied for following Kaplan-Meier analysis, and high expression of BIRC5, CENPA and FAM64A in this cohort were found to be related to poor survival (OS, DMFS, DFS and RFS). This correlation was also seen in patients at early stages and grades. On the other hand, the outcome of patients with synchronous upregulation of these three genes was the worst, while those with synchronous low gene level was the best. In conclusion, BIRC5, CENPA and FAM64A are specifically upregulated in TNBC, and the high expression of these three genes is associated with poor breast cancer prognosis, suggesting their clinical implication as therapeutic targets in TNBC.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Mahamodhossen YA, Liu W and Rong-Rong Z: Triple-negative breast cancer: new perspectives for novel therapies. Med Oncol. 30:6532013. View Article : Google Scholar : PubMed/NCBI
7.	Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8:235–244. 2007. View Article : Google Scholar
8.	Schneider BP, Winer EP, Foulkes WD, et al: Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 14:8010–8018. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Bosch A, Eroles P, Zaragoza R, Viña JR and Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Balko JM, Cook RS, Vaught DB, et al: Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med. 18:1052–1059. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Ur-Rehman S, Gao Q, Mitsopoulos C and Zvelebil M: ROCK: a resource for integrative breast cancer data analysis. Breast Cancer Res Treat. 139:907–921. 2013.PubMed/NCBI
12.	van de Vijver MJ, He YD, van’t Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
13.	Chin K, DeVries S, Fridlyand J, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Butte A: The use and analysis of microarray data. Nat Rev Drug Discov. 1:951–960. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Han Y, Huang H, Xiao Z, et al: Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One. 7:e527452012. View Article : Google Scholar : PubMed/NCBI
16.	Konstantinopoulos PA, Cannistra SA, Fountzilas H, et al: Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One. 6:e182022011. View Article : Google Scholar
17.	Richardson AL, Wang ZC, De Nicolo A, et al: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 9:121–132. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Brown MP, Grundy WN, Lin D, et al: Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA. 97:262–267. 2000. View Article : Google Scholar : PubMed/NCBI
19.	Perreard L, Fan C, Quackenbush JF, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 8:R232006. View Article : Google Scholar : PubMed/NCBI
20.	Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
21.	Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer - current status and future directions. Ann Oncol. 20:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar
24.	Hinnis AR, Luckett JC and Walker RA: Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007. View Article : Google Scholar : PubMed/NCBI
25.	Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA and Sweep FC: Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem. 52:1693–1700. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Islam A, Kageyama H, Takada N, et al: High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 19:617–623. 2000. View Article : Google Scholar : PubMed/NCBI
27.	Regnier V, Vagnarelli P, Fukagawa T, et al: CENP-A is required for accurate chromosome segregation and sustained kinetochore association of BubR1. Mol Cell Biol. 25:3967–3981. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Amato A, Schillaci T, Lentini L and Di Leonardo A: CENPA overexpression promotes genome instability in pRb-depleted human cells. Mol Cancer. 8:1192009. View Article : Google Scholar : PubMed/NCBI
29.	Archangelo LF, Greif PA, Maucuer A, et al: The CATS (FAM64A) protein is a substrate of the Kinase Interacting Stathmin (KIS). Biochim Biophys Acta. 1833:1269–1279. 2013. View Article : Google Scholar : PubMed/NCBI
30.	Takagi K, Miki Y, Shibahara Y, et al: BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients. Horm Cancer. 4:92–102. 2013. View Article : Google Scholar : PubMed/NCBI
31.	Li L, Xu DB, Zhao XL and Hao TY: Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer. Arch Gynecol Obstet. 288:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
32.	Hegyi K and Mehes G: Mitotic failures in cancer: Aurora B kinase and its potential role in the development of aneuploidy. Pathol Oncol Res. 18:761–769. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Takeshita M, Koga T, Takayama K, et al: Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. Lung Cancer. 80:85–90. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Tchatchou S, Wirtenberger M, Hemminki K, et al: Aurora kinases A and B and familial breast cancer risk. Cancer Lett. 247:266–272. 2007. View Article : Google Scholar : PubMed/NCBI